{"id":"NCT00053677","sponsor":"University of Chicago","briefTitle":"Drug Treatment for Pathologic Gambling Disorder","officialTitle":"Naltrexone Treatment in Pathologic Gambling Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-12","primaryCompletion":"2005-11","completion":"2005-11","firstPosted":"2003-02-05","resultsPosted":"2017-10-03","lastUpdate":"2023-02-23"},"enrollment":83,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Gambling"],"interventions":[{"type":"DRUG","name":"Naltrexone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Naltrexone","type":"PLACEBO_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder (PGD) and severe urge symptoms.","primaryOutcome":{"measure":"Yale-Brown Obsessive Compulsive Scale for Pathological Gambling (PG-YBOCS)","timeFrame":"18 weeks","effectByArm":[{"arm":"Naltrexone","deltaMin":16.9,"sd":6.6},{"arm":"Placebo","deltaMin":18.6,"sd":4.9}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["11377409","9590665","11552772","11780876","11728609","11447570"],"seeAlso":["http://www.impulsecontroldisorders.org/index.html"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Nausea","Headache","Diarrhea","Dry Mouth","Dizziness"]}}